Aprio Wealth Management LLC Has $821,000 Stock Position in Astrazeneca Plc $AZN

Aprio Wealth Management LLC lifted its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 58.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,926 shares of the company’s stock after buying an additional 3,277 shares during the period. Aprio Wealth Management LLC’s holdings in Astrazeneca were worth $821,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of AZN. Cibc World Market Inc. grew its position in Astrazeneca by 21.5% during the 3rd quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock worth $4,942,000 after acquiring an additional 11,398 shares during the last quarter. TD Asset Management Inc grew its position in Astrazeneca by 20.0% during the 3rd quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock worth $83,595,000 after acquiring an additional 181,273 shares during the last quarter. Y Intercept Hong Kong Ltd grew its position in Astrazeneca by 111.6% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 66,643 shares of the company’s stock worth $5,113,000 after acquiring an additional 35,148 shares during the last quarter. AMG National Trust Bank grew its position in Astrazeneca by 20.4% during the 3rd quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock worth $3,298,000 after acquiring an additional 7,289 shares during the last quarter. Finally, Oxbow Advisors LLC grew its position in Astrazeneca by 96.2% during the 3rd quarter. Oxbow Advisors LLC now owns 77,594 shares of the company’s stock worth $5,953,000 after acquiring an additional 38,043 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Weiss Ratings assumed coverage on Astrazeneca in a research report on Wednesday, March 11th. They set a “buy (b)” rating on the stock. Wall Street Zen lowered Astrazeneca from a “buy” rating to a “hold” rating in a research report on Saturday, April 4th. Citigroup assumed coverage on Astrazeneca in a research report on Tuesday, January 27th. They set a “buy” rating on the stock. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Finally, Barclays restated an “overweight” rating on shares of Astrazeneca in a research report on Tuesday, January 6th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $102.67.

Astrazeneca Trading Down 1.3%

NYSE AZN opened at $187.30 on Tuesday. Astrazeneca Plc has a 12 month low of $132.32 and a 12 month high of $212.71. The stock has a market capitalization of $290.48 billion, a price-to-earnings ratio of 32.27, a P/E/G ratio of 1.43 and a beta of 0.35. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94.

Astrazeneca Announces Dividend

The business also recently declared a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were given a $1.595 dividend. This represents a dividend yield of 156.0%. The ex-dividend date was Friday, February 20th. Astrazeneca’s payout ratio is 74.83%.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.